Diacerein ( DrugBank: Diacerein )
3 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 36 | 表皮水疱症 | 16 |
| 46 | 悪性関節リウマチ | 1 |
| 63 | 特発性血小板減少性紫斑病 | 1 |
36. 表皮水疱症
臨床試験数 : 163 / 薬物数 : 185 - (DrugBank : 46) / 標的遺伝子数 : 50 - 標的パスウェイ数 : 125
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2018-000439-29-GB (EUCTR) | 04/06/2018 | 22/03/2018 | A Multi-center Study to Evaluate How CCP-020 (Diacerein 1% ointment) is Absorbed in the Blood and Removed from the Body in Patients with Epidermolysis Bullosa (EB) | A Multi-center Study to Evaluate the Pharmacokinetics of Diacerein and Rhein and the Safety of Diacerein after Maximum Use, Topical Administration of CCP-020 (Diacerein 1% ointment) to Patients with Epidermolysis Bullosa (EB) | Epidermolysis Bullosa (EB) MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: Diacerein Product Code: CCP-020 INN or Proposed INN: DIACEREIN | Castle Creek Pharmaceuticals, LLC | NULL | Not Recruiting | Female: yes Male: yes | 4 | Phase 1 | United States;France;Netherlands;Germany;United Kingdom | ||
| 2 | NCT03472287 (ClinicalTrials.gov) | May 18, 2018 | 14/3/2018 | To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullosa (EB) | A Multi-Center Study to Evaluate the Pharmacokinetics of Diacerein and Rhein and the Safety of Diacerein After Maximum Use, Topical Administration of CCP-020 (Diacerein 1% Ointment) to Patients With Epidermolysis Bullosa (EB) | Epidermolysis Bullosa (EB);Epidermolysis Bullosa Simplex;Dystrophic Epidermolysis Bullosa;Junctional Epidermolysis Bullosa | Drug: Diacerein 1% Ointment | Castle Creek Pharmaceuticals, LLC | NULL | Completed | 4 Years | N/A | All | 11 | Phase 1 | United States;France;Netherlands;United Kingdom |
| 3 | EUCTR2017-003757-41-DE (EUCTR) | 19/04/2018 | 21/02/2018 | An International Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) | An International, Multicenter, Open-label, Long Term Extension Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) | Epidermolysis Bullosa Simplex (EBS) MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: Diacerein Product Code: Diacerein INN or Proposed INN: DIACEREIN Other descriptive name: Diacerein | Castle Creek Pharmaceuticals, LLC | NULL | Not Recruiting | Female: yes Male: yes | 80 | Phase 2 | United States;France;Austria;Australia;Israel;Netherlands;Germany;United Kingdom;Italy | ||
| 4 | EUCTR2017-003757-41-NL (EUCTR) | 11/04/2018 | 06/12/2017 | An International Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) | An International, Multicenter, Open-label, Long Term Extension Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) | Epidermolysis Bullosa Simplex (EBS) MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: Diacerein Product Code: Diacerein INN or Proposed INN: DIACEREIN Other descriptive name: Diacerein | Castle Creek Pharmaceuticals, LLC | NULL | Not Recruiting | Female: yes Male: yes | 80 | Phase 2 | United States;France;Austria;Australia;Israel;Germany;Netherlands;United Kingdom;Italy | ||
| 5 | EUCTR2017-003757-41-GB (EUCTR) | 19/02/2018 | 13/11/2017 | An International Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) | An International, Multicenter, Open-label, Long Term Extension Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) | Epidermolysis Bullosa Simplex (EBS) MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: Diacerein Product Code: Diacerein INN or Proposed INN: DIACEREIN Other descriptive name: Diacerein | Castle Creek Pharmaceuticals, LLC | NULL | Not Recruiting | Female: yes Male: yes | 80 | Phase 2 | United States;France;Austria;Australia;Israel;Netherlands;Germany;Italy;United Kingdom | ||
| 6 | EUCTR2017-003757-41-FR (EUCTR) | 07/02/2018 | 17/10/2018 | An International Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) | An International, Multicenter, Open-label, Long Term Extension Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) | Epidermolysis Bullosa Simplex (EBS) MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: Diacerein Product Code: Diacerein INN or Proposed INN: DIACEREIN Other descriptive name: Diacerein | Castle Creek Pharmaceuticals, LLC | NULL | Not Recruiting | Female: yes Male: yes | 80 | Phase 2 | United States;France;Austria;Australia;Israel;Netherlands;Germany;United Kingdom | ||
| 7 | EUCTR2017-003757-41-AT (EUCTR) | 04/01/2018 | 29/11/2017 | An International Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) | An International, Multicenter, Open-label, Long Term Extension Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) | Epidermolysis Bullosa Simplex (EBS) MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: Diacerein Product Code: Diacerein INN or Proposed INN: DIACEREIN Other descriptive name: Diacerein | Castle Creek Pharmaceuticals, LLC | NULL | Not Recruiting | Female: yes Male: yes | 84 | Phase 2 | France;United States;Australia;Austria;Israel;Netherlands;Germany;Italy;United Kingdom | ||
| 8 | NCT03389308 (ClinicalTrials.gov) | December 1, 2017 | 19/12/2017 | Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex | An International, Multicenter, Open-label, Long Term Extension Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex (EBS) | Epidermolysis Bullosa;Epidermolysis Bullosa Simplex | Drug: diacerein 1% ointment | Castle Creek Pharmaceuticals, LLC | NULL | Completed | 6 Months | 99 Years | All | 51 | Phase 2 | United States |
| 9 | EUCTR2016-004427-24-AT (EUCTR) | 10/10/2017 | 30/05/2017 | An International Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) | An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) [DELIVERS Study] | Epidermolysis Bullosa Simplex (EBS) MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: Diacerein Product Code: Diacerein INN or Proposed INN: DIACEREIN Other descriptive name: Diacerein | Castle Creek Pharmaceuticals, LLC | NULL | Not Recruiting | Female: yes Male: yes | 80 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | France;United States;Australia;Austria;Israel;Netherlands;Germany;Italy;United Kingdom | ||
| 10 | EUCTR2016-004427-24-NL (EUCTR) | 06/09/2017 | 23/06/2017 | An International Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) | An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) [DELIVERS Study] | Epidermolysis Bullosa Simplex (EBS) MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: Diacerein Product Code: Diacerein INN or Proposed INN: DIACEREIN Other descriptive name: Diacerein | Castle Creek Pharmaceuticals, LLC | NULL | Not Recruiting | Female: yes Male: yes | 80 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | France;United States;Austria;Australia;Israel;Germany;Netherlands;Italy;United Kingdom | ||
| 11 | EUCTR2016-004427-24-DE (EUCTR) | 24/08/2017 | 23/05/2017 | An International Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) | An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) [DELIVERS Study] | Epidermolysis Bullosa Simplex (EBS) MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: Diacerein Product Code: Diacerein INN or Proposed INN: DIACEREIN Other descriptive name: Diacerein | Castle Creek Pharmaceuticals, LLC | NULL | Not Recruiting | Female: yes Male: yes | 80 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | France;United States;Austria;Australia;Israel;Netherlands;Germany;Italy;United Kingdom | ||
| 12 | EUCTR2016-004427-24-GB (EUCTR) | 21/07/2017 | 06/07/2017 | An International Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) | An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) [DELIVERS Study] | Epidermolysis Bullosa Simplex (EBS) MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: Diacerein Product Code: Diacerein INN or Proposed INN: DIACEREIN Other descriptive name: Diacerein | Castle Creek Pharmaceuticals, LLC | NULL | Not Recruiting | Female: yes Male: yes | 80 | Phase 2 | France;United States;Austria;Australia;Israel;Netherlands;Germany;Italy;United Kingdom | ||
| 13 | NCT03154333 (ClinicalTrials.gov) | June 1, 2017 | 10/5/2017 | Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS) | An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex | Epidermolysis Bullosa Simplex | Drug: diacerein 1% ointment;Drug: A placebo ointment | Castle Creek Pharmaceuticals, LLC | NULL | Terminated | 4 Years | N/A | All | 54 | Phase 2 | United States;Australia;Austria;France;Germany;Israel;Netherlands;United Kingdom |
| 14 | EUCTR2013-002034-21-AT (EUCTR) | 16/12/2013 | 01/08/2013 | Diacerein for butterfly children | Diacerein for the treatment of Epidermolysis bullosa simplex - Diacerein for EBS | Epidermolysis bullosa simplex - type Dowling-Meara;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: SimpleCare INN or Proposed INN: DIACEREIN | EB House Austria | NULL | Not Recruiting | Female: yes Male: yes | Phase 3 | Austria | |||
| 15 | EUCTR2016-004427-24-FR (EUCTR) | 21/08/2017 | An International Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) | An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) | Epidermolysis Bullosa Simplex (EBS) MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: Diacerein Product Code: Diacerein INN or Proposed INN: DIACEREIN Other descriptive name: Diacerein | Castle Creek Pharmaceuticals, LLC | NULL | Not Recruiting | Female: yes Male: yes | 80 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | United States;France;Austria;Australia;Israel;Netherlands;Germany;United Kingdom | |||
| 16 | EUCTR2018-000439-29-NL (EUCTR) | 27/09/2018 | A Multi-center Study to Evaluate How CCP-020 (Diacerein 1% ointment) is Absorbed in the Blood and Removed from the Body in Patients with Epidermolysis Bullosa (EB) | A Multi-center Study to Evaluate the Pharmacokinetics of Diacerein and Rhein and the Safety of Diacerein after Maximum Use, Topical Administration of CCP-020 (Diacerein 1% ointment) to Patients with Epidermolysis Bullosa (EB) | Epidermolysis Bullosa (EB) MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: Diacerein Product Code: CCP-020 INN or Proposed INN: DIACEREIN | Castle Creek Pharmaceuticals, LLC | NULL | NA | Female: yes Male: yes | 20 | Phase 1 | France;United States;Germany;Netherlands;United Kingdom |
46. 悪性関節リウマチ
臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01264211 (ClinicalTrials.gov) | October 2010 | 28/6/2010 | Safety and Efficacy of the Combination of Diacerein 100 mg Daily and MTX Versus MTX Alone in the Treatment of Early Rheumatoid Arthritis (RA) | A 6-month Pilot Randomised Double-blind Placebo-controlled Multicentre, Phase 2 Study | Rheumatoid Arthritis | Drug: Diacerein;Drug: Placebo | TRB Chemedica | NULL | Completed | 18 Years | 65 Years | Both | 40 | Phase 2 | Thailand |
63. 特発性血小板減少性紫斑病
臨床試験数 : 391 / 薬物数 : 235 - (DrugBank : 50) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 139
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04917679 (ClinicalTrials.gov) | September 1, 2020 | 1/12/2020 | Eltrombopag Plus Diacerein vs Eltrombopag in Adult ITP | Eltrombopag Plus Diacerein vs Eltrombopag in Adult Primary Immune Thrombocytopenia: a Multicenter Randomized Controlled Trial | Thrombocytopenia | Drug: Eltrombopag plus diacerein;Drug: Eltrombopag | Qilu Hospital of Shandong University | NULL | Recruiting | 18 Years | N/A | All | 100 | Phase 2 | China |